OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Seymour on Shifting Standards of Care in CLL

September 25th 2018

Erlene Seymour, MD, an oncologist at Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses shifting standards of care in chronic lymphocytic leukemia (CLL).

Dr. van den Bent on Temozolomide and Depatux-M in Glioblastoma

September 25th 2018

Martin J. van den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, the Netherlands, discusses the combination of temozolomide (Temodal) and depatuxizumab mafodotin (depatux-m) in the treatment of patients with glioblastoma.

Dr. Radich on the Potential of Biosimilars in Oncology

September 25th 2018

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses the potential of biosimilars in oncology.

Dr. O'Donnell on the Evolution of Immunotherapy in Metastatic Bladder Cancer

September 25th 2018

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses the evolution of immunotherapy in metastatic bladder cancer.

Dr. Flinn on the FDA Approval of Duvelisib in CLL and Follicular Lymphoma

September 25th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.

Dr. Eggermont Discusses Impact of Pembrolizumab in Melanoma

September 24th 2018

Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the impact of pembrolizumab in melanoma.

Dr. Ferris on the CheckMate-041 Trial For Head and Neck Cancer

September 24th 2018

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute discusses the significance of the CheckMate-041 trial for patients with head and neck cancer.

Dr. Stadler on Sequencing Therapies in Prostate Cancer

September 22nd 2018

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses sequencing therapies in prostate cancer.

Dr. Sweis on Immunotherapy in Genitourinary Cancer

September 22nd 2018

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the use of immunotherapy in genitourinary cancer.

Dr. Nghiem on Challenges With Immunotherapy in Merkel Cell Carcinoma

September 22nd 2018

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses challenges with immunotherapy in patients with Merkel cell carcinoma

Dr. Steinberg on BCG Progression in Non-Muscle Invasive Bladder Cancer

September 22nd 2018

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses bacillus Calmette-Guérin (BCG) progression in non-muscle invasive bladder cancer (NMIBC).

Dr. Rule on Rituximab Biosimilar Use in the UK

September 22nd 2018

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses the use of biosimilars in the United Kingdom for the treatment of cancer.

Dr. Konstantinopoulos Discusses PARP Plus Immunotherapy

September 22nd 2018

Panagiotis A. Konstantinopoulos, MD, PhD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the combination of PARP inhibitors and immunotherapy.

Dr. Cohen on the Evolution of Antibodies in Lymphoma

September 22nd 2018

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the evolution of antibodies for the treatment of lymphoma.

Dr. Primrose on Adjuvant Capecitabine For Biliary Tract Cancer

September 21st 2018

John Primrose, MD, ChB, FRCS, professor of medicine/surgery, University of Southampton, United Kingdom, discusses the impact of adjuvant capecitabine in patients with biliary tract cancer.

Dr. Gentzler on Combination Therapies in NSCLC

September 21st 2018

Ryan D. Gentzler, MD, assistant professor, Division of Hematology/Oncology, University of Virginia Health System, discusses combination therapies in non–small cell lung cancer (NSCLC).

Dr. Graff on Novel Therapies in Metastatic Breast Cancer

September 21st 2018

Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses novel therapies for patients with metastatic breast cancer.

Dr. Singh on Treatment for Patients With Uterine Leiomyosarcoma

September 21st 2018

Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses treatment for patients with uterine leiomyosarcoma.

Dr. Madduri Discusses Checkpoint Inhibitors in Myeloma

September 20th 2018

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses the use of checkpoint inhibitors in multiple myeloma.

Dr. Shiller on Next-Generation Sequencing in GI Cancers

September 20th 2018

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses next-generation sequencing in gastrointestinal malignancies.